CCR4 and its ligands: from bench to bedside

This article is a brief overview of basic and clinical research on CCR4 and its ligands, which has eventually led to the development of a humanized defucosylated anti-CCR4 antibody ‘Mogamulizumab’ for treatment of relapsed/refractory ATL and CTCLs.

Source: International Immunology - December 30, 2014 Category: Allergy & Immunology Authors: Yoshie, O., Matsushima, K. Tags: Invited review Source Type: research